Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria.

ABSTRACT:

Background

Chronic spontaneous urticaria (CSU) negatively impacts patients' sleep, thereby reducing health-related quality of life (HRQoL). Half of patients with inadequately controlled CSU report sleep interference often or every night, which can lead to depression, anxiety, social, and work-related problems.

Methods

This randomized, double-blind, placebo-controlled Phase 2b core study (NCT02477332) included adult patients ≥18 years with moderate to severe CSU inadequately controlled with H₁ -antihistamines. The current analysis includes patients randomized to receive ligelizumab 72 or 240 mg, omalizumab 300 mg or placebo every 4 weeks (q4w) for five injections over 20 weeks with treatment-free follow-up for 24 weeks. Patients could enter the open-label extension

SUBMITTER: Gimenez-Arnau A 

PROVIDER: S-EPMC8848195 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature